What is the current stock price of Pyxis Oncology, Inc. (PYXS)?

As of the latest market data, Pyxis Oncology, Inc. (PYXS) is trading at $1.70. The stock has seen a gain of 5.59% today.

Does Pyxis Oncology, Inc. (PYXS) pay a dividend?

Based on current data, Pyxis Oncology, Inc. does not have a confirmed active dividend policy.

What is the market cap of Pyxis Oncology, Inc.?

The current market capitalization of Pyxis Oncology, Inc. (PYXS) is approximately unavailable.

PYXS

Pyxis Oncology, Inc.·Healthcare

1.70

5.590%(+0.09)

Market Closed

1.78

4.706%(+0.08)

After Hours

Last Updated: — ET

52W L: $0.8752W H: $5.55

PYXS NEWS

globenewswire.com

Mar 23

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026

defenseworld.net

Mar 10

Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Pyxis Oncology to announce earnings of ($0.35) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the

defenseworld.net

Feb 21

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the

globenewswire.com

Feb 3

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals.

defenseworld.net

Feb 2

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Currently, 4.1% of the company's stock are short sold. Based on an

Company Profile

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-10-08

Beta

1.42

Websitewww.pyxisoncology.com↗